CENCORA INC
CORNYSETrading Snapshot
- Day Range
- $300.79 β $309.79
- 52-Week Range
- $244.82 β $377.54
- Volume
- $3.20B
- Avg Volume
- $3.93B
- Shares Outstanding
- 194.6M
- Next Earnings
- Nov 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $321.33B
- Last Q Revenue
- $84.75B
- P/E Ratio
- 22.5
- P/S Ratio
- 0.2x
- EPS (TTM)
- $13.59
- Dividend Yield
- 0.79%
- Dilution (1yr)
- +0.1%
Why Investors Own COR
- βHigh-growth profile β revenue up +16.6% YoY with expanding US Equity exposure.
- βHealthy economics β 26% gross margin and 15% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CENCORA INC
CORAbout CENCORA INC
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Cencora Elects Robert E. Sanchez to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executi

Here's Why Cencora (COR) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Cencora NYSE: COR executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and moment

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference
Cencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while rea

Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $COR
Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,601 s